1 December 2022 - Evidence is rated as promising but inconclusive to determine whether fezolinetant provides a net health benefit for patients over the long term; however, using point estimates from short-term clinical trials, analyses suggest this drug would achieve common thresholds for cost-effectiveness if priced between $2,000- $2,500 per year for women who cannot or choose not to take menopausal hormone therapy.

The ICER today posted its revised evidence report assessing the comparative clinical effectiveness and value of fezolinetant (Astellas) for the vasomotor symptoms associated with menopause.

Read ICER Announcement